Abstract
Conjunctival lymphoma is a malignant growth of lymphoid cells on the ocular surface. Clinically, it can present either as a salmon patch or as a follicular form. The etiology of this type of cancer remains unknown, although new research has demonstrated a possible link to infectious agents including Chlamydia psittaci and hepatitis C. When the lymphoma is localized, the current standard of care is external beam radiation, although new therapeutic options include intralesional injections of interferon or rituximab. If systemic, treatment options now include doxycycline, rituximab (Rituxan), and Y-90 ibritumomab tiuxetan (Zevalin). This article explores the new research and treatment options for conjunctival lymphoma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 63-67 |
| Number of pages | 5 |
| Journal | Techniques in Ophthalmology |
| Volume | 9 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2011 |
ASJC Scopus subject areas
- Ophthalmology
UN SDGs
This output contributes to the following Sustainable Development Goal(s)
